Last €0.03 EUR
Change Today +0.006 / 22.22%
Volume 0.0
IBT On Other Exchanges
Symbol
Exchange
Stuttgart
Venture
OTC US
As of 2:17 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

ibex technologies inc (IBT) Snapshot

Open
€0.03
Previous Close
€0.03
Day High
€0.03
Day Low
€0.03
52 Week High
07/10/14 - €0.04
52 Week Low
10/23/13 - €0.02
Market Cap
815.2K
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
24.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBEX TECHNOLOGIES INC (IBT)

Related News

No related news articles were found.

ibex technologies inc (IBT) Related Businessweek News

No Related Businessweek News Found

ibex technologies inc (IBT) Details

IBEX Technologies Inc., a biopharmaceutical company, engages in the production and sale of proprietary enzymes for use as reagents in hemostasis monitoring devices. The company also provides arthritis diagnostic kits, including Collagen Type II Cleavage Assay that measures real-time collagen type II degradation; Collagen Type I and II Cleavage Assay, which measures the amount of real-time collagen of types I and II degradation; CPII Assay-Cartilage that monitors changes in the rate of synthesis of cartilage components of type II collagen indicative of osteoarthritis and rheumatoid arthritis; and Aggrecan Chondroitin Sulfate 846 Epitope Assay, which monitors changes in the rate of synthesis of cartilage components of aggrecan indicating osteoarthritis and rheumatoid arthritis. IBEX offers its arthritis diagnostic kits primarily for the pharmaceutical research. In addition, the company provides cartilage biomarker antibodies comprising Ab1320 Aggrecan NITEGE rabbit, Col M, Type IX Collagen, and C1-2C. Further, it offers heparinase II and heparinase III research reagents; chondroitinase AC that acts as a research reagent, and involved in degradation of hyaluronic acid; and chondroitinase B, a research reagent. Additionally, the company provides sample testing services. It sells its products primarily in Canada, the United States, and Europe. The company is based in Montreal, Canada.

ibex technologies inc (IBT) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$246.6K
Director of Finance and Secretary
Total Annual Compensation: C$32.8K
Compensation as of Fiscal Year 2013.

ibex technologies inc (IBT) Key Developments

IBEX Technologies, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended April 30, 2014; Provides Cash Flow Guidance for 2014 and 2015

IBEX Technologies, Inc. announced consolidated earnings results for the third quarter and nine months ended April 30, 2014. For the quarter, the company reported sales totaled $1,140,228 compared to $922,007 in the previous quarter and $1,268,908 in the same period of the prior year. Earnings were $148,844 compared to a loss of $2,922 in the previous quarter and a loss of $122,030 in the year-ago period. For the nine months, the company reported sales totaled $2,941,351, an increase of 6% compared to the same period in 2013 $2,764,912. Earnings before interests, tax, depreciation and amortization were $68,367 against loss before interests, tax, depreciation and amortization of $289,191 a year ago. Net loss was $258,097 against $521,637 a year ago. Basic and diluted loss per share was 0.01 cents against 0.02 cents a year ago. For 2014 and 2015, the company expects cash flow positive  in fiscal 2014 nor possibly in fiscal 2015.

Ibex Technologies Inc. Reports Earnings Results for Second Quarter and Six Months Ended January 31, 2014

IBEX Technologies Inc. reported earnings results for second quarter and six months ended January 31, 2014. The company's sales for the quarter ended January 31, 2014 totaled CAD 922,007 compared to CAD 741,666 in the same period of the prior year. The loss for the period was CAD 2,922 compared to a loss of CAD 468,277 in the year ago period. The reduction in loss is mainly attributable to IBEX Pharma which had net earnings of CAD 168,273, offset by a loss in BRP of CAD 171,195. The BRP operating loss for this period included three months' activity compared to one month's activity for the same period year ago. The company's sales for the six months ended January 31, 2014 totaled CAD 1,801,123, an increase of 20% compared to the same period in 2013 of CAD 1,496,004. The company recorded a net loss of CAD 406,941 compared to a net loss of CAD 399,607 for the same period year ago. The principle part of this loss derived from BRP which had an operating loss of CAD 375,604. Loss before interests, tax, depreciation & amortization was CAD 184,603 against CAD 305,753 a year ago. Loss per share basic and diluted was CAD 0.02 against CAD 0.02 a year ago.

IBEX Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2013; Provides Cash Flow Guidance for the Fiscal Year 2014 and 2015

IBEX Technologies, Inc. reported earnings results for the first quarter ended October 31, 2013. Sales for the quarter ended October 31, 2013 totaled CAD 879,116 compared to CAD 754,338 in the same period of the prior year. This year's figure included sales of CAD 282,121 from Bio-Research Products Inc. (BRP) which did not appear in the year ago results. The Company recorded a net loss of CAD 404,019 or CAD 0.02 per basic and diluted share compared to net earnings of CAD 68,670 or CAD 0.00 per basic and diluted share for the same period year ago. This decrease in net earnings is attributable to a loss in IBEX Pharmaceuticals Inc. of CAD 199,609 due to lower sales of IBEX enzyme reagents and a loss of CAD 204,410 at BRP. Loss before interests, tax, depreciation & amortization was CAD 292,405 compared to earnings before interests, tax, depreciation & amortization of CAD 100,243 in the same period of the prior year. Operating loss for the first quarter ended October 31, 2013 was CAD 402,751, compared to an operating income of CAD 50,174, for the same quarter ended October 31, 2012. Sales for the period were up 16% versus year ago due to a positive quarter for arthritis assays (up 90%), heparinase-based diagnostic components (up 3%) and the inclusion of sales from the newly acquired BioResearch Products Inc. Sales for enzyme reagents however were down 50% due to the previously reported hiatus in purchasing by a major customer. The company provided cash flow guidance for the fiscal year 2014 and 2015. Fiscal 2014 and Fiscal 2015 will be challenging years for the Company. As previously announced, there will be hiatus in sales from one of major customers (due to excess inventory on their side) resulting in a cut back in purchases over the next two years. In the event the Company is not able to replace the sales from this major customer with new contracts, it will not be in a cash flow positive position in Fiscal 2014, and possibly in Fiscal 2015. The Company has been working on a number of projects with major customers, some of which it hopes will result in significant revenue in the latter part of Fiscal 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBT:GR €0.03 EUR +0.006

IBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBT.
View Industry Companies
 

Industry Analysis

IBT

Industry Average

Valuation IBT Industry Range
Price/Earnings 4.3x
Price/Sales 0.3x
Price/Book 0.3x
Price/Cash Flow 4.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBEX TECHNOLOGIES INC, please visit www.ibex.ca. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.